These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 27429040

  • 1. Progress and Perspectives on HIV-1 microbicide development.
    Alexandre KB, Mufhandu HT, London GM, Chakauya E, Khati M.
    Virology; 2016 Oct; 497():69-80. PubMed ID: 27429040
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Development of topical microbicides to prevent the sexual transmission of HIV.
    Buckheit RW, Watson KM, Morrow KM, Ham AS.
    Antiviral Res; 2010 Jan; 85(1):142-58. PubMed ID: 19874851
    [Abstract] [Full Text] [Related]

  • 4. Microbicides: still a long road to success.
    Vanpouille C, Arakelyan A, Margolis L.
    Trends Microbiol; 2012 Aug; 20(8):369-75. PubMed ID: 22705107
    [Abstract] [Full Text] [Related]

  • 5. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides.
    Keller MJ, Herold BC.
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S92-5. PubMed ID: 19218889
    [Abstract] [Full Text] [Related]

  • 6. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention.
    Gaym A.
    Ethiop Med J; 2006 Oct; 44(4):405-15. PubMed ID: 17370443
    [Abstract] [Full Text] [Related]

  • 7. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F, Ruiz-Caro R, Veiga-Ochoa MD.
    Drug Des Devel Ther; 2017 Oct; 11():1767-1787. PubMed ID: 28670111
    [Abstract] [Full Text] [Related]

  • 8. HIV infection of the genital mucosa in women.
    Hladik F, Hope TJ.
    Curr HIV/AIDS Rep; 2009 Feb; 6(1):20-8. PubMed ID: 19149993
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
    Martinez J, Coplan P, Wainberg MA.
    Antiviral Res; 2006 Sep; 71(2-3):343-50. PubMed ID: 16787667
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Microbicides: putting women in control.
    Forbes A.
    WORLD; 1998 Sep; (89):4-5. PubMed ID: 11365770
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission.
    Nikolic DS, Piguet V.
    J Invest Dermatol; 2010 Feb; 130(2):352-61. PubMed ID: 19829304
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Microbicides for prevention of HIV infection: clinical efficacy trials.
    Abdool Karim SS, Baxter C.
    Curr Top Microbiol Immunol; 2014 Feb; 383():97-115. PubMed ID: 23695725
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.